





Ceramide Metabolism and Catabolism**FIGURE 1.****FIGURE 2.**

**FIGURE 3.****FIGURE 4.**




FIGURE 5.




FIGURE 6.




FIGURE 7.






FIGURE 8

D-threo-PPMP Increases Ceramide more than L-Threo-PPMP**FIGURE 9.****FIGURE 10**

D-threo-PPMP more potently synergizes 4-HPR cytotoxicity in a prostate cell line





FIGURE 11.

Synthetic Route of D-threo-PPMP




FIGURE 12.

Continuous venous infusion of intravenous 4-HPR in rat

4-HPR Levels in Rat Tissue and Rat Plasma																
ANIMAL # and:	Liver		Brain		Lungs		Heart		Kidney		Adrenal		Bladder		Plasma	
Dose [mg/kg/day]	HPR	MPR	HPR	MPR	HPR	MPR	HPR	MPR	HPR	MPR	HPR	MPR	HPR	MPR	HPR	MPR
Length of T. [days]	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	ug/g	uM	uM
RP-4 (90 mg, 2 d)	63.5	2.0	17.4	2.0	61.6	4.0	68.9	2.2	65.5	2.9	117.7	11.2	12.2	1.4	45.3	4.1
RP-5 (90 mg, 4 d)	123.1	7.7	15.5	1.6	129.3	8.8	111.3	4.8	109.1	6.6	195.1	21.0	30.3	4.6	80.7	10.8
RP-9 (120 mg, 5 d)*	153.8	5.9	38.2	5.5	158.3	9.7	148.6	4.9	119.3	7.1	339.7	17.7	30.7	7.7	53.5	3.5
RP-2 (150 mg, 3 d)**	60.1	20.3	26.0	5.1	65.1	15.4	66.9	9.9	72.3	16.8	140.9	31.9	28.4	5.8	57.0	41.0

NM=not measured

Cremophor/4-HPR

Liposome/4-HPR*

Emulsion/4-HPR**

FIGURE 13